Literature DB >> 20362629

Increased prolyl endopeptidase activity in human neoplasia.

Gorka Larrinaga1, Itxaro Perez, Lorena Blanco, José I López, Leire Andrés, Carmen Etxezarraga, Francisco Santaolalla, Aitor Zabala, Adolfo Varona, Jon Irazusta.   

Abstract

Prolyl endopeptidase (EC 3.4.21.26) (PEP) is a serine peptidase that converts several biologically active peptides. This enzyme has been linked to several neurological, digestive, cardiovascular and infectous disorders. However, little is known about its involvement in neoplastic processes. This study analyzes fluorimetrically cytosolic and membrane-bound PEP activity in a large series (n=122) of normal and neoplastic tissues from the kidney, colon, oral cavity, larynx, thyroid gland and testis. Cytosolic PEP activity significantly increased in clear cell renal cell carcinoma, urothelial carcinoma of the renal pelvis and head and neck squamous cell carcinoma. Both cytosolic and membrane-bound PEP activity were also increased in colorectal adenomatous polyps. These data suggest the involvement of PEP in some mechanisms that underlie neoplastic processes. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20362629     DOI: 10.1016/j.regpep.2010.03.012

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  14 in total

1.  Tetrazole as a Replacement of the Electrophilic Group in Characteristic Prolyl Oligopeptidase Inhibitors.

Authors:  Tommi P Kilpeläinen; Jonna K Tyni; Maija K Lahtela-Kakkonen; Tony S Eteläinen; Timo T Myöhänen; Erik A A Wallén
Journal:  ACS Med Chem Lett       Date:  2019-11-11       Impact factor: 4.345

2.  Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.

Authors:  T T Myöhänen; J Tenorio-Laranga; B Jokinen; R Vázquez-Sánchez; M J Moreno-Baylach; J A García-Horsman; P T Männistö
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

3.  Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors.

Authors:  Timo T Myöhänen; Elisa Pyykkö; Pekka T Männistö; Olli Carpen
Journal:  J Histochem Cytochem       Date:  2012-06-26       Impact factor: 2.479

4.  Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer.

Authors:  Ricardo E Perez; Sarah Calhoun; Daeun Shim; Victor V Levenson; Lei Duan; Carl G Maki
Journal:  Cancer Biol Ther       Date:  2020-10-12       Impact factor: 4.742

5.  Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Tamyra D Downs; Patrick A McKee
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

6.  Dipeptidyl-peptidase IV activity is correlated with colorectal cancer prognosis.

Authors:  Gorka Larrinaga; Itxaro Perez; Begoña Sanz; Maider Beitia; Peio Errarte; Ainhoa Fernández; Lorena Blanco; María C Etxezarraga; Javier Gil; José I López
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

7.  Altered Activity and Expression of Cytosolic Peptidases in Colorectal Cancer.

Authors:  Itxaro Perez; Lorena Blanco; Begoña Sanz; Peio Errarte; Usue Ariz; Maider Beitia; Ainhoa Fernández; Alberto Loizate; M Luz Candenas; Francisco M Pinto; Javier Gil; José I López; Gorka Larrinaga
Journal:  Int J Med Sci       Date:  2015-06-02       Impact factor: 3.738

8.  Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase.

Authors:  Kenneth W Jackson; Victoria J Christiansen; Vivek R Yadav; Robert Silasi-Mansat; Florea Lupu; Vibhudutta Awasthi; Roy R Zhang; Patrick A McKee
Journal:  Neoplasia       Date:  2015-01       Impact factor: 5.715

9.  Prolyl endopeptidase activity is correlated with colorectal cancer prognosis.

Authors:  Gorka Larrinaga; Itxaro Perez; Lorena Blanco; Begoña Sanz; Peio Errarte; Maider Beitia; María C Etxezarraga; Alberto Loizate; Javier Gil; Jon Irazusta; José I López
Journal:  Int J Med Sci       Date:  2014-01-10       Impact factor: 3.738

10.  Altered peptidase activities in thyroid neoplasia and hyperplasia.

Authors:  Gorka Larrinaga; Lorena Blanco; Peio Errarte; Maider Beitia; Begoña Sanz; Itxaro Perez; Amaia Irazusta; Clara E Sánchez; Francisco Santaolalla; Leire Andrés; José I López
Journal:  Dis Markers       Date:  2013-11-27       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.